Recent Updates — CODX

Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics in August 2026 to evaluate the compatibility of ReadyGo's sample collection and preparation technologies with Co-Diagnostics' Co-Dx PCR platform. Under this preliminary arrangement, ReadyGo will provide sampling materials for feasibility studies aimed at streamlining the sample-to-result workflow for decentralized testing environments. The agreement does not obligate either party to enter into future development or commercial arrangements, and there is no assurance that these evaluations will result in additional agreements. Co-Diagnostics operates in the molecular diagnostics industry, developing point-of-care PCR testing platforms.

Co-Diagnostics, Inc. announced that Brian Brown departed as Chief Financial Officer and Principal Accounting Officer effective September 2, 2026. Daniel Bohrer was appointed to serve as the new principal financial officer and principal accounting officer. In connection with this appointment, Mr. Bohrer's annual salary increased from $225,000 to $255,000. Co-Diagnostics operates in the healthcare diagnostics industry, developing molecular diagnostic tests.